Ruedin P
Praxis (Bern 1994). 1999 Jan 28;88(5):173-7.
The treatment of renal anaemia with human recombinant erythropoietin (r-hu-EPO) in predialysis patients requires a close collaboration between the general practitioner and the nephrologist. This therapeutic option, along with other measures as part of the management of patients with renal insufficiency, is aimed at slowing down the progression of the kidney failure and at maintaining the patient in the best possible metabolic conditions. This paper summarises the benefits and risks of r-hu-EPO administered in renal insufficiency. The practical guidelines for the r-hu-EPO administration should help to assure an optimal and cost-effective utilization of the treatment.
对于透析前患者，使用重组人促红细胞生成素（r-hu-EPO）治疗肾性贫血需要全科医生和肾病科医生密切合作。这种治疗选择与作为肾功能不全患者管理一部分的其他措施一起，旨在减缓肾衰竭的进展，并使患者维持在尽可能最佳的代谢状态。本文总结了在肾功能不全患者中使用r-hu-EPO的益处和风险。r-hu-EPO给药的实用指南应有助于确保该治疗的最佳利用和成本效益。
